Drug & intervention
lutetium Lu 177 dotatate
RxCUI 1999335
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
3 shown177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast CancerNCT04529044 · 2026-06-30
RECRUITINGTesting the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine CellsNCT05691465 · 2023-12-27
RECRUITINGTesting Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsNCT04665739 · 2023-02-03
RECRUITINGConditions being studied
Advanced Lung Neuroendocrine Tumor1Anatomic Stage IV Breast Cancer AJCC v81Functioning Lung Neuroendocrine Tumor1Locally Advanced Lung Neuroendocrine Neoplasm1Lung Neuroendocrine Neoplasm1Lung Neuroendocrine Tumor G11Lung Neuroendocrine Tumor G21Metastatic Breast Carcinoma1Metastatic Lung Neuroendocrine Neoplasm1Metastatic Lung Neuroendocrine Tumor1Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation1Metastatic Prostate Neuroendocrine Carcinoma1Metastatic Prostate Small Cell Neuroendocrine Carcinoma1Non-Functioning Lung Neuroendocrine Tumor1Recurrent Breast Carcinoma1Recurrent Lung Neuroendocrine Neoplasm1Stage IVB Prostate Cancer AJCC v81Unresectable Lung Neuroendocrine Neoplasm1Unresectable Lung Neuroendocrine Tumor1
Research locations
ChicagoIllinois, United States2ColumbusOhio, United States2Los AngelesCalifornia, United States2AventuraFlorida, United States1BaltimoreMaryland, United States1Beverly HillsCalifornia, United States1BirminghamAlabama, United States1BostonMassachusetts, United States1ClevelandOhio, United States1Coral GablesFlorida, United States1DallasTexas, United States1Des MoinesIowa, United States1
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.